Patients with UC receiving steroids during the presymptomatic period showed a trend, although not statistically significant, towards reduced probability of developing symptomatic disease (25% vs. 62%, p = 0.06; aOR 0.21, 95% CI [0.038–1.087]; log‐rank = 0.9), and patients with preclinical CD did not show a difference on this risk (100% vs. 65%, p = 0.67; aOR 1.07, 95% CI [0.94–1.21]; log‐rank = 0.51).
← all excerpts
Subclinical bowel inflammation increases healthcare resources utilization and steroid use before diagnosis of inflammatory bowel disease.
1
—
—